Advertisement

Topics

Summit Therapeutics Announces Positive Top-Line Data From An Exploratory Phase II Clinical Trial Supporting Ridinilazole As A Highly Selective Antibiotic For The Treatment Of CDI

20:00 EDT 4 Sep 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Summit Therapeutics Announces Positive Top-Line Data From An Exploratory Phase II Clinical Trial Supporting Ridinilazole As A Highly Selective Antibiotic For The Treatment Of CDI

NEXT ARTICLE

More From BioPortfolio on "Summit Therapeutics Announces Positive Top-Line Data From An Exploratory Phase II Clinical Trial Supporting Ridinilazole As A Highly Selective Antibiotic For The Treatment Of CDI"

Quick Search
Advertisement